Program
Immunoglobulin G
Also written as “HYQVIA”, “HyQvia” and “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”.
Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Prostatic Neoplasms · Autoimmune Diseases of the Nervous System · Alzheimer Disease, led by 6 companies.
Drug pageImmunoglobulin G: every studyMany companies study it; this page follows only the 13 they lead. All 241 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 60 open or running | phase 4since Apr 12, 2017 | Sep 11, 2015 | none ahead |
| GC Biopharmaits history only | 30 open or running | phase 4since Jan 25, 2012 | Mar 14, 2011 | none ahead |
| CSLits history only | 10 open or running | phase 3since May 16, 2008 | May 16, 2008 | none ahead |
| Genmabits history only | 10 open or running | phase 2since May 14, 2020 | May 14, 2020 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 1since May 30, 2025 | May 30, 2025 | none ahead |
| Proclara Biosciencesits history only | 10 open or running | phase 1since Dec 23, 2016 | Dec 23, 2016 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, AbbVie and Symyoo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 16, 2008First study: phase 3 study in Primary Immunodeficiency DiseasesNew to CSLCSL · NCT00680446 · 41 enrolled · Australia, New Zealand
- Mar 14, 2011GC Biopharma’s first study: phase 3 study in SepsisNew to GC BiopharmaGC Biopharma · NCT01315496 · 214 enrolled · Korea, Republic of
- Jan 25, 2012Phase 4 study in Mucocutaneous Lymph Node SyndromeGC Biopharma · NCT01524939 · 45 enrolled · Korea, Republic of
- Sep 11, 2015Takeda’s first study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNew to TakedaTakeda · NCT02549170 · 138 enrolled · United States, Argentina, Brazil and more
- Nov 2, 2016Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingTakeda · NCT02955355 · 85 enrolled · United States, Argentina, Brazil and more
- Dec 23, 2016Proclara Biosciences’ first study: phase 1 study in Alzheimer DiseaseNew to Proclara BiosciencesProclara Biosciences · NCT03008161 · 83 enrolled · United States
- Apr 12, 2017Phase 4 study in Primary Immunodeficiency DiseasesTakeda · NCT03116347 · 42 enrolled · Czechia, Denmark, France and more
- Sep 7, 2017Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT03277313 · 44 enrolled · United States
- Nov 21, 2019Phase 2 study in Autoimmune Diseases of the Nervous SystemGC Biopharma · NCT04175522 · 23 enrolled · Korea, Republic of
- May 14, 2020Genmab’s first study: phase 2 study in Prostatic NeoplasmsNew to GenmabGenmab · NCT04424641 · 48 enrolled · United States, Denmark, Israel and more
- Jul 7, 2020Phase 1 study in Healthy VolunteersTakeda · NCT04578535 · 51 enrolled · United States
- Mar 20, 2025Phase 1 study in Healthy VolunteersTakeda · NCT06895967 · 30 enrolled · United States
- May 30, 2025Hoffmann-La Roche’s first study: phase 1 study in Healthy ParticipantsNew to Hoffmann-La RocheHoffmann-La Roche · NCT07025577 · 82 enrolled · United States
- Oct 19, 2026Primary completion moved from 2028-02-28 to 2029-05-06Date moved laterphase 2 · +14 months · NCT07048262
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07025577Healthy Participants · United States | 1 | Completed | Hoffmann-La Roche | Aug 8, 2025 | 82 |
| NCT06895967Healthy Volunteers · United States | 1 | Completed | Takeda | Jul 24, 2025 | 30 |
| NCT04578535Healthy Volunteers · United States | 1 | Completed | Takeda | Mar 2, 2022 | 51 |
| NCT04424641Prostatic Neoplasms · United States, Denmark, Israel and more | 2 | Terminated | Genmab | Oct 29, 2021 | 48 |
| NCT04175522Autoimmune Diseases of the Nervous System · Korea, Republic of | 2 | Completed | GC Biopharma | Jun 11, 2020 | 23 |
| NCT03277313Primary Immunodeficiency Diseases · United States | 3 | Completed | Takeda | Jul 20, 2022 | 44 |
| NCT03116347Primary Immunodeficiency Diseases · Czechia, Denmark, France and more | 4 | Completed | Takeda | Jan 15, 2021 | 42 |
| NCT03008161Alzheimer Disease · United States | 1 | Completed | Proclara Biosciences | Feb 6, 2019 | 83 |
| NCT02955355Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more | 3 | Completed | Takeda | Jul 4, 2023 | 85 |
| NCT02549170Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more | 3 | Completed | Takeda | Feb 23, 2022 | 138 |
| NCT01524939Mucocutaneous Lymph Node Syndrome · Korea, Republic of | 4 | Completed | GC Biopharma | Sep 2012 | 45 |
| NCT01315496Sepsis · Korea, Republic of | 3 | Terminated | GC Biopharma | Dec 2013 | 214 |
| NCT00680446Primary Immunodeficiency Diseases · Australia, New Zealand | 3 | Completed | CSL | May 2013 | 41 |
How it is read
Names in the registry
- “HYQVIA”, 10 entries
- “Immunoglobulin G”, 3 entries
- “HyQvia”, 1 entry
- “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”, 1 entry
- “NPT088”, 1 entry
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 3 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Prostatic Neoplasms, 1 study
- Autoimmune Diseases of the Nervous System, 1 study
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.